Nanobiotix ( (NBTX) ) just unveiled an announcement.
On May 5, 2025, Nanobiotix announced the full results from a completed Phase 1 study of JNJ-1900 (NBTXR3) in pancreatic cancer, presented at the European Society of Radiation Oncology meeting. The study showed promising safety and efficacy outcomes, with a median overall survival of 23 months and a median local progression-free survival of 13.3 months. The findings support further evaluation in a randomized study, potentially impacting treatment strategies for pancreatic cancer, a disease with limited therapeutic options.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
Nanobiotix faces significant financial and operational challenges, reflected in its financial performance score. However, the strategic partnership with JNJ and pipeline advancements provide some optimism, albeit overshadowed by negative profitability and valuation metrics. Technical indicators suggest neutral to slightly bearish sentiment.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company that focuses on pioneering nanotherapeutic approaches to improve treatment outcomes for cancer patients. The company is engaged in developing JNJ-1900 (NBTXR3), a novel oncology product designed to enhance the effectiveness of radiotherapy across various solid tumors.
YTD Price Performance: 15.21%
Average Trading Volume: 11,153
Technical Sentiment Signal: Buy
Current Market Cap: $162.6M
For detailed information about NBTX stock, go to TipRanks’ Stock Analysis page.